E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability.
Maes, Michael, Mihaylova, Ivana, Leunis, Jean-Claude · Journal of affective disorders · 2007 · DOI
Quick Summary
This study found that people with ME/CFS have higher levels of immune antibodies (IgA and IgM) that react against bacteria normally found in the gut. The researchers suggest this indicates the gut barrier may be more permeable (leaky), allowing bacterial products to enter the bloodstream and trigger an immune response. The study suggests testing for these antibodies might help identify and treat this potential gut problem in ME/CFS patients.
Why It Matters
Understanding potential gut barrier dysfunction and bacterial involvement in ME/CFS could open new diagnostic and treatment approaches. If validated, antibody testing against these bacteria might help identify a biomarker for a subset of ME/CFS patients and guide targeted interventions addressing intestinal permeability.
Observed Findings
- Serum IgA and IgM levels against enterobacterial LPS are significantly elevated in CFS patients compared to normal controls and partial CFS patients.
- Serum IgA levels correlate with illness severity as measured by the FibroFatigue scale.
- IgA levels correlate with specific symptoms: irritable bowel, muscular tension, fatigue, concentration difficulties, and failing memory.
Inferred Conclusions
- Gram-negative enterobacteria are implicated in CFS etiology.
- Increased intestinal permeability allows enterobacterial LPS translocation and triggers immune sensitization in CFS patients.
- IgA panel testing could serve as a diagnostic tool and guide treatment of gut permeability in CFS.
Remaining Questions
- What is the sample size and does it have adequate statistical power to detect differences between groups?
- Does increased intestinal permeability precede CFS symptom onset, or does it develop secondary to illness?
- Would interventions targeting intestinal permeability or enterobacteria reduce CFS symptoms and normalize antibody levels?
- Are these antibody elevations specific to CFS or present in other chronic inflammatory conditions?
What This Study Does Not Prove
This study does not prove that enterobacteria or gut permeability causes ME/CFS—it only shows an association. The cross-sectional design cannot determine whether increased antibodies precede ME/CFS symptoms or result from the illness. The study also does not demonstrate that treating gut permeability would improve ME/CFS symptoms.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →